Metabolic Solutions Development CO

Kalamazoo, MI 49007

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $2.82MM
First Award Date 05/01/09
Most Recent Award Date 09/23/14

Key Personnel

Last Name Name Awards Contact
Kletzien Rolf F Kletzien 8
Murphy Anne N Murphy 3
Finck Brian N Finck 3
COLCA JERRY RAYMOND COLCA 1

8 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-055
Budget: 09/23/14 - 08/31/15

DESCRIPTION (provided by applicant): Polycystic kidney disease (PKD) is a term applied to a group of inherited disorders characterized by the presence of cysts in the kidney although multiple organs are typically affected. Renal pathologies found in essentially all forms of PKD include increased fluid secretion, matrix remodeling, cellular proli...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-051
Budget: 09/10/12 - 08/31/13

DESCRIPTION (provided by applicant): Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the United States. This condition encompasses both hepatic steatosis and the more severe non-alcoholic steatohepatitis. It is now estimated that 14-24% of the general population and up to 80% of morbidly obese subjects have contr...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-051
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the United States. This condition encompasses both hepatic steatosis and the more severe non-alcoholic steatohepatitis. It is now estimated that 14-24% of the general population and up to 80% of morbidly obese subjects have contr...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-051
Budget: 09/15/11 - 08/31/12

DESCRIPTION (provided by applicant): Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the United States. This condition encompasses both hepatic steatosis and the more severe non-alcoholic steatohepatitis. It is now estimated that 14-24% of the general population and up to 80% of morbidly obese subjects have contr...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 04/01/11 - 03/31/12

DESCRIPTION (provided by applicant): The overall objective of our proposed research is to discover a PPARg-free thiazolidinedione (TZD) which shows antidiabetic activity in a rodent model of Type 2 diabetes and demonstrates the necessary drug-like qualities to become a clinical candidate for human therapeutics. The insulin sensitizing agents of ...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 04/01/10 - 03/31/11

DESCRIPTION (provided by applicant): The overall objective of our proposed research is to discover a PPARg-free thiazolidinedione (TZD) which shows antidiabetic activity in a rodent model of Type 2 diabetes and demonstrates the necessary drug-like qualities to become a clinical candidate for human therapeutics. The insulin sensitizing agents of ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/01/09 - 06/30/10

DESCRIPTION (provided by applicant): The overall objective of the proposed research is to discover a PPAR?-sparing thiazolidinedione (TZD) which displays efficacy in a rodent model of non-alcoholic fatty liver disease (NAFLD) and demonstrates the necessary drug-like qualities to become a potential clinical candidate for human therapeutics. The T...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 05/01/09 - 11/30/09

DESCRIPTION (provided by applicant): The overall objective of our proposed research is to discover a PPARg-free thiazolidinedione (TZD) which shows antidiabetic activity in a rodent model of Type 2 diabetes and demonstrates the necessary drug-like qualities to become a clinical candidate for human therapeutics. The insulin sensitizing agents of ...